What STADA Portugal does

STADA Portugal (legal name STADA Lda.) is the Portuguese pharmaceutical subsidiary of STADA Arzneimittel AG, a German pharmaceutical group founded in 1895 and listed on the Frankfurt Stock Exchange (ticker: STM). Established in Portugal in 2005 and headquartered in Paço de Arcos (Lisbon metropolitan area), the company distributes a diversified portfolio of prescription medicines (MSRM), over-the-counter (OTC) medications, medical devices, food supplements, and cosmetics through pharmacy networks across Portugal. It serves healthcare professionals, pharmacists, and patients/consumers, with emphasis on affordable generics and self-care products. STADA Portugal operates with approximately 36 local employees as a sales, marketing, and distribution entity, while manufacturing and R&D are centralized within the parent group's European production network.

The product portfolio spans approximately 45+ branded SKUs across multiple therapeutic categories. Flagship OTC brands include Nizoral (antifungal shampoo with a renewed Nizoral Care line), Hirudoid (topical heparinoid for venous disorders), Elmetacin (topical NSAID, including a CBD variant), Mebocaína (throat care), Hoggar (doxylamine sleep aid), Grippostad (ibuprofen/phenylephrine cold and flu), Tavegyl (allergy), and HeperPoll (cetirizine). Medical devices include the Hedrin lice-treatment range (launched 2024) and MAR seawater-based nasal hygiene products. The Lactoflora family covers food supplements for urinary, immune, intestinal, menopausal, and rehydration health. The MSRM division spans cardiovascular, gastroenterology, anti-infectives, allergies, central nervous system, rheumatology, and metabolic disease categories. Underlying technology includes the parent group's biosimilars development program (requiring biotechnology expertise) and large-scale manufacturing capacity of over 1 billion tablets, 1 billion capsules, and 1,000 tonnes of cream annually across European production centers, with strict quality control from development through production.

The revenue model is built on pharmaceutical product sales through pharmacy distribution channels. At the group level, generics contribute 58% of revenue and OTC, oncology, and other therapeutic areas contribute 42%. Pricing is regulated under Portuguese pharmaceutical frameworks and is not publicly disclosed at the product level. STADA Portugal functions as a channel-partner-driven distribution subsidiary, with corporate communications and product-specific websites (e.g., nizoral.pt, hirudoid.pt, hedrin.pt, lactoflora.pt) supporting top-of-funnel consumer and pharmacist engagement rather than direct e-commerce. ESG and regulatory compliance are central to the operating posture: the group achieved EcoVadis Gold, Sustainalytics Low Risk Score (top 3% in pharmaceuticals), CDP Climate Change B rating, and ISO 50001 certification in 2024, and STADA Portugal maintains a dedicated compliance and pharmacovigilance contact infrastructure.

Name

STADA Portugal

Legal name

STADA Lda.

Website

https://stada.pt

Company type

Public

Founded year

1895

Operating status

Operating

Short description

STADA Portugal (STADA Lda.) is the Portuguese pharmaceutical subsidiary of Germany's STADA Arzneimittel AG, distributing OTC medications, prescription medicines, medical devices, and food supplements through Portuguese pharmacy networks since 2005.

Ownership category

akta.pro rank

Product category

Consumer Health Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG)

akta.pro secondary industries

Probiotics & Digestive Health Supplements (CRADAGAF), Vitamins & Minerals (Single Nutrients) (CRADAGAB)

Keywords

• Generic pharmaceuticals
• OTC medications
• Consumer health products
• Medical devices
• Food supplements

Headquarters

HQ city

Paço de Arcos

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: STADA generates revenue through the sale of pharmaceutical products including generic medicines (58% of revenue) and OTC products, oncology, and other therapeutic specialties (42% of revenue).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

STADA Portugal (STADA Lda.) distributes a diversified pharmaceutical and consumer health portfolio in Portugal, encompassing prescription medications (MSRM), over-the-counter (OTC) medicines, medical devices, food supplements, and cosmetics. Products are sold under well-known brands including Nizoral (antifungal), Hirudoid (venous disorders), Elmetacin (topical NSAID), Hedrin (lice treatment), Lactoflora (food supplements), Mebocaína (throat care), Venoruton, Hoggar, and Grippostad. The company serves patients and consumers through pharmacy networks across Portugal, leveraging the parent STADA Group's manufacturing scale and over 125 years of pharmaceutical heritage.

Product overview

STADA Portugal offers a diversified pharmaceutical and consumer health portfolio encompassing prescription medications (MSRM), over-the-counter (OTC) medications, medical devices, food supplements, and cosmetics. The core OTC products include Nizoral (antifungal shampoo), Hirudoid (venous disorders), Elmetacin (topical NSAID), and Mebocaína (throat care). The medical device line features Hedrin (lice treatment) and MAR (seawater nasal hygiene). The Lactoflora line provides food supplements for urinary, intestinal, immune, and intimate health. The MSRM division covers prescription medications across cardiovascular, gastroenterology, anti-infectives, allergies, CNS, rheumatology, and metabolic diseases. STADA also develops biosimilars requiring biotechnology expertise and high-quality standards. The portfolio includes approximately 45+ distinct branded products targeting various therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• Nizoral: Medication containing ketoconazole for treatment and prevention of infections such as pityriasis versicolor, seborrheic dermatitis, and dandruff. Includes Nizoral Care line with conditioner and shampoos for dry, sensitive, and oily scalp.
• Hirudoid
• Elmetacin
• Hedrin
• Flexital
• HeperPoll
• Mobilisin
• Lactoflora
• MAR
• SNUP
• Venoruton
• Mebocaína
• Hoggar
• Urinal TEST
• Grippostad
• Tavegyl
• Mobiflex
• Mitosyl

Products and services

• Nizoral® Non-prescription antifungal medication containing ketoconazole, indicated for treatment and prevention of infections such as pityriasis versicolor, seborrheic dermatitis, and dandruff. Includes the Nizoral Care line (tonic and shampoos) for scalp care.
• Hirudoid® Non-prescription topical medication containing heparinoid, indicated as adjunctive symptomatic treatment of superficial venous disorders, varicose syndrome, hematoma, sprains, and bruises.
• Elmetacin® Non-prescription topical NSAID containing indomethacin, indicated for painful and inflammatory conditions of the locomotor system. Also available in a CBD variant.
• Hedrin Complete range of medical devices and cosmetics for all phases of lice and nits infestation, color-coded by phase (detection, treatment, post-treatment, protection).
• Lactoflora® Range Food supplement range including Lactoflora Uro (cranberries, probiotics, vitamin C for urinary tract), Lactoflora Imuno (lactobacilli, vitamins, minerals for immune system), Lactoflora Intestinal (symbiotic with Bifidobacterium lactis, Lactobacillus acidophilus, L. plantarum, L. paracasei), Lactoflora Menopausa, Lactoflora Protetor íntimo, and Lactoflora Soro de Reidratação (oral rehydration salts).
• Mebocaína® Range Non-prescription throat medications including Mebocaína Forte (tyrothricin, cetylpyridinium chloride, oxybuprocaine hydrochloride for sore throat), Mebocaína Anti-Inflam (dichlorobenzyl alcohol and benzidamine hydrochloride for inflammatory throat conditions), and Mebocaína Protect Lima-Mentol.
• Hoggar® Non-prescription medication containing doxylamine, indicated for short-term symptomatic treatment of occasional sleep disorders in adults.
• Grippostad OTC medication containing ibuprofen and phenylephrine hydrochloride, indicated for relief of cold and flu symptoms including mild to moderate pain, nasal congestion, and fever reduction in adults and adolescents over 12 years of age.
• MSRM Prescription Medications Portfolio Prescription-only medications (Medicamentos Sujeitos a Receita Médica) spanning multiple therapeutic areas: anti-infectives (Aciclovir, Amoxicillin+Clavulanic acid, Azithromycin, Ciprofloxacin, Levofloxacin, Moxifloxacin, Terbinafine), allergies (Cetirizine, Desloratadine, Levocetirizine, Montelukast), anti-inflammatories (Aceclofenac, Celecoxib, Etoricoxib, Meloxicam, Nimesulide), cardiovascular (Amlodipine, Atorvastatin, Bisoprolol, Candesartan, Carvedilol, Clopidogrel, Enalapril, Losartan, Nebivolol, Rosuvastatin, Simvastatin, Telmisartan, Valsartan), gastroenterology (Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole), metabolic diseases (Glimepiride, Metformin), rheumatology (Alendronic acid, Allopurinol, Glucosamine), and CNS (Agomelatine, Aripiprazole, Duloxetine, Escitalopram, Fluoxetine, Gabapentin, Memantine, Mirtazapine, Paracetamol, Pregabalin, Quetiapine, Sertraline, Tramadol, Venlafaxine).
• Biosimilars STADA's biosimilars development program represents a key R&D focus area, requiring extensive biotechnology experience and high-quality standards to ensure safety and therapeutic equivalence as required by the scientific community and health authorities. STADA is one of the few companies involved in biosimilars development.
• MAR® Medical devices for daily nasal and oral hygiene, made with 100% natural seawater collected at depth from ecological areas of the North Atlantic. Includes MAR Bebé, MAR Suave, and MAR Forte variants.
• SNUP® Non-prescription nasal decongestant medication containing a unique combination of Xylometazoline Hydrochloride and Sea Water.
• Urinal® TEST Self-test medical device for detecting urinary tract infections at home, with results in approximately 2 minutes.
• Mobilisin® Non-prescription topical NSAID containing flufenamic acid and mucopolysaccharide polysulfate, for local treatment of inflammatory conditions of muscles, tendons, ligaments, joints, and rheumatic diseases.
• Venoruton Non-prescription orange-flavoured medication containing oxerutins from plants, indicated for systemic treatment of symptoms related to venous insufficiency (venous edema, pain, heaviness, tension, tingling, and itching in legs).
• Flexital® Balm formulation with 25% urea, developed for deep skin penetration and intense hydration to treat dry and cracked skin on feet and heels.
• HeperPoll® maçã Non-prescription allergy medication containing cetirizine in apple-flavoured chewable tablets, indicated for relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis and urticaria.
• Tavegyl Non-prescription allergy and anti-pruritic medication indicated for relief of nasal allergic symptoms (rhinorrhea and nasal congestion) and/or cutaneous symptoms (itching, insect bites), for use from 6 years of age.
• Mobiflex® Joint Nutrition Range Joint nutrition and care range including Mobiflex Intensive (glucosamine and chondroitin for joint, cartilage, ligament, and tendon health) and Mobiflex Gel (fast-absorbing gel for joint massage to improve mobility of joints, muscles, and tendons).
• Mitosyl® Range Protective ointment range for baby care including Mitosyl Pomada Protetora (cod liver oil formula for delicate baby skin, protects against irritants such as urine and feces, available in 65g, 145g, and 2x145g packs) and Mitosyl Bálsamo Primeiros Dentes (balm for baby's gums during teething with lactoserum and Mentha piperita).
• Hiruspray Pernas Cansadas Medical device spray for tired legs.
• ViruProtect STADA Medical device for viral protection of the oral cavity.
• Lactease® Food supplement for lactose intolerance support.
• Flatucone Food supplement for flatulence relief.

Quantifiable outcome

• 58% revenue from generic medicines ensures broad market access
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• STADA Arzneimittel AG (Parent Company)coreOthersSTADA Portugal operates as a subsidiary of the international STADA Group headquartered in Germany. The parent company develops, manufactures, and commercializes pharmaceutical products globally. STADA Portugal benefits from the group's 125+ years of expertise, extensive product portfolio, and shared commitment to sustainability and quality.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Zentiva: European-focused generics and OTC pharmaceutical company headquartered in Prague, operating across multiple European markets including Portugal. Zentiva offers a comparable generics-plus-OTC portfolio distributed through pharmacy channels, making it the closest direct comparable to STADA Portugal's business model and market positioning.
• Krka: Slovenian pharmaceutical company with a generics and OTC portfolio distributed across more than 70 countries. Krka's vertical integration from API to finished generics, combined with broad European presence including Iberian markets, makes it a strong comparable to STADA Portugal in both business model and product mix.
• Medochemie: Cyprus-based multinational pharmaceutical company with a generics-led portfolio across therapeutic categories, operating in over 100 countries including European markets. Medochemie's vertical integration and OTC/generics mix make it a structurally comparable peer to STADA.

Broad incumbents

• Teva Pharmaceutical Industries: Global leader in generics with a broad specialty pharma portfolio. Teva operates in Portugal and competes across the same prescription generics and OTC categories, but its global scale, biosimilars franchise, and specialty focus make it a broader incumbent rather than a direct peer.
• Sandoz: Novartis's generics and biosimilars division, spun off as a publicly listed entity. Sandoz competes directly with STADA in generics and biosimilars across European markets including Portugal, with significantly greater scale and a leading biosimilar pipeline.
• Viatris: Global pharmaceutical company formed from Mylan and Upjohn, with a substantial generics and biosimilars portfolio. Viatris serves Portugal and competes across therapeutic areas overlapping with STADA, but operates at materially larger scale.
• Recordati: Italian pharmaceutical group operating across prescription pharmaceuticals, rare diseases, and consumer health across Europe. Recordati serves Portugal through its broader European distribution network and competes with STADA in OTC and specialty therapeutic categories.

Regional players

• Tecnimede: Portuguese pharmaceutical group operating in generics, branded medicines, and healthcare products with strong local market knowledge. As a home-grown Portuguese competitor, Tecnimede competes head-to-head with STADA Portugal in the local pharmacy channel.
• Polpharma: Poland's largest pharmaceutical manufacturer with a generics, OTC, and API portfolio across Central and Eastern Europe, increasingly expanding into Western Europe. While primarily focused on CEE, Polpharma's portfolio structure and generics-plus-OTC model mirror STADA's.
• Alfasigma: Italian pharmaceutical company combining prescription drugs, OTC, and food supplements with distribution across European markets. Alfasigma's OTC and consumer health focus, particularly in Southern European markets, makes it a partial comparable to STADA Portugal's portfolio mix.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/stada
• Facebookfacebook.com/Stada
• LinkedInlinkedin.com/company/stada

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STADA Portugal